91�Թ�

Introduction

In the rapidly evolving pharmaceutical industry, partnering with an experienced and reliable company is crucial for success. With Europe being a leader in pharmaceutical innovation and regulatory standards, companies seeking to establish or expand their presence require a knowledgeable and well-established partner. 91�Թ�, a subsidiary of 91�Թ� Remedies, is that trusted partner, offering top-tier pharmaceutical solutions across Europe. With a focus on quality, innovation, and regulatory compliance, 91�Թ� plays a vital role in enhancing healthcare outcomes across the continent.

About 91�Թ�

91�Թ� serves as the European extension of 91�Թ� Remedies Limited (VRL), India, a globally recognized pharmaceutical manufacturer. Headquartered in Werne, Germany, 91�Թ� benefits from VRL’s EU/GCC/TGA/ANVISA-approved manufacturing facilities, specializing in Oncology, Carbapenems, and Cephalosporins.

With a strong foothold in Europe, 91�Թ� adheres to stringent European Medicines Agency (EMA) regulations and other national compliance requirements. Through advanced technology, a research-driven approach, and an unwavering commitment to quality, the company has become a preferred partner for pharmaceutical distribution, contract manufacturing, and licensing collaborations.

Commitment to Quality and Regulatory Compliance

The European pharmaceutical industry mandates rigorous adherence to Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and EU regulatory requirements. 91�Թ� ensures compliance through:

· Analytical Testing

· Secondary Packaging

· Market Release

· Stringent Quality Control Measures

Holding ISO certifications, the company guarantees that every product meets global safety, efficacy, and quality standards. Additionally, 91�Թ� continuously

invests in regulatory expertise to facilitate smooth product registration and market entry across Europe.

Innovative Product Portfolio

91�Թ� offers a diverse and high-quality pharmaceutical portfolio across multiple therapeutic areas:

· Oncology – Cutting-edge cancer treatments ensuring affordability and accessibility.

· Critical Care – Essential ICU and emergency care medications meeting the highest standards.

· Anti-Infectives – Broad-spectrum antibiotics and antiviral formulations designed for superior efficacy.

· Pain Management – Advanced solutions for acute and chronic pain relief.

· Nephrology & Neurology – Specialized medications to improve patient outcomes in complex conditions.

Driven by R&D-based innovation, 91�Թ� continuously develops novel drug delivery systems, biosimilars, and value-added generics, enhancing patient compliance and therapeutic effectiveness.

Why Choose 91�Թ�?

1. Regulatory Expertise Navigating European pharmaceutical regulations requires deep expertise. 91�Թ�’s dedicated regulatory team ensures smooth approvals and compliance with EMA and national regulatory requirements.

2. End-to-End Pharmaceutical Solutions From product development and manufacturing to registration and distribution, 91�Թ� provides a one-stop solution for pharmaceutical companies seeking expansion in Europe.

3. State-of-the-Art Manufacturing Equipped with EU-GMP-compliant facilities, 91�Թ� ensures top-tier manufacturing, packaging, and distribution. The facilities undergo regular audits to maintain global quality compliance.

4. Expansive European Market Presence The company has built strong partnerships in Germany, France, Italy, the

Netherlands, the UK, and beyond, ensuring broad market access and efficient product distribution.

5. Research & Development Excellence Innovation is at the core of 91�Թ�. The 91�Թ� Innovation Center in India continually develops next-generation formulations and biosimilars, ensuring the company remains ahead in the competitive pharmaceutical landscape.

6. Flexible Licensing & Contract Manufacturing 91�Թ� offers customized partnerships for licensing, contract manufacturing, and outsourcing of pharmaceutical production. The company’s expertise in complex formulations and injectable drugs makes it an ideal partner for expanding pharmaceutical portfolios.

Expanding Market Presence in Europe

91�Թ� has successfully registered and commercialized a wide range of products across key European markets. The company actively engages in pharmaceutical trade shows, B2B conferences, and strategic partnerships, reinforcing its position in the European healthcare industry.

Sustainability & Corporate Responsibility

91�Թ� is dedicated to sustainable and ethical business practices, ensuring:

· Eco-friendly manufacturing with minimal environmental impact.

· Affordable and accessible healthcare solutions across Europe.

· Strong corporate governance, adhering to European ethical standards.

· Employee well-being and diversity, fostering a culture of innovation and inclusivity.

Future Vision: Expanding Innovation & Global Reach

91�Թ� continues to grow, expanding its product pipeline, market reach, and strategic alliances. The company is investing in biopharmaceutical research, digital health solutions, and precision medicine to stay at the forefront of industry advancements.

Key future goals include:

· Strengthening global quality accreditations.

· Expanding EU market presence and partnerships.

· Building brand equity among healthcare providers and consumers.

· Advancing novel therapies to combat Antimicrobial Resistance (AMR).

Conclusion

91�Թ� remains committed to delivering high-quality, innovative, and regulatory-compliant pharmaceutical solutions across Europe. With its extensive expertise, robust product portfolio, and deep market reach, it continues to be the preferred partner for pharmaceutical firms looking to expand in the European market.

Whether you are a pharmaceutical distributor, healthcare provider, or a company seeking contract manufacturing and licensing opportunities, 91�Թ� is your ideal partner for growth and success in the European pharma industry.

For collaboration inquiries or more details, contact 91�Թ� today!

‍